What Angelini Ventures does

Angelini Ventures S.p.A. is the corporate venture capital arm of Angelini Industries, an Italian privately-held diversified industrial group headquartered in Rome. Founded in October 2022, the firm manages €300 million in committed capital for investments in BioTech and HealthTech companies globally, with a December 2025 partnership adding a further €150 million co-investment commitment from the European Investment Bank. The firm invests primarily in Series A and Series B rounds across Europe, North America, and Asia, with eight offices including a November 2025 Singapore regional headquarters. Its portfolio of 16+ companies spans gene therapy, antibody-drug conjugates, radiopharmaceuticals, brain monitoring, AI-powered care delivery, women's health, and CNS therapeutics.

The firm's core offering is its venture capital investment platform, augmented by an internally-developed AI-powered deal evaluation tool called "Investor Score" that applies statistical modeling and data-driven frameworks to startup selection. The firm operates two venture studios that create proprietary deal flow: Extend, a translational BRIDGE joint venture with Evotec and CDP Venture Capital developing drug discovery partnerships from Italian academic research, and Argobio, a European startup studio for biotech spinouts. The Angelini Lumira Bioscience Fund, a partnership with Lumira Partners, focuses specifically on early-stage CNS companies in North America. Portfolio outcomes to date include the $340 million ResMed acquisition of Noctrix Health in June 2026 (the firm's first exit), the FDA authorization of Noctrix's Nidra therapy for Restless Legs Syndrome, and measurable clinical outcomes from portfolio company Nobi (51% fall reduction in care facilities).

The firm generates returns through capital appreciation and exits from portfolio companies, with management fees funded by its €300 million Angelini Industries commitment. Over $80 million has been deployed across more than 10 new investments in the first two years of operation. Distribution is direct: the firm engages founders through active board representation, strategic guidance on clinical development, and network access across a global syndicate of co-investors. The team of approximately 11-50 professionals is led by CEO Paolo Di Giorgio and includes Managing Directors Elia Stupka, Tanja Dowe, and Regina Hodits, alongside senior investment, medical, data science, and operations leads.

Name

Angelini Ventures

Legal name

Angelini Ventures S.p.A.

Website

https://angeliniventures.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Angelini Ventures S.p.A. is Angelini Industries' corporate venture capital arm, deploying €300 million in BioTech and HealthTech Series A and B rounds globally. Founded in 2022, the firm operates eight offices and runs a proprietary AI-powered deal evaluation platform.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

All Other Financial Investment Activities (52399), Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital investing
• Biotech investment
• Healthtech investment
• Healthcare venture capital
• Life sciences funding

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Investment Returns: Angelini Ventures generates returns through capital appreciation and exits from its portfolio companies. The firm invests €300 million globally in BioTech and HealthTech companies, targeting transformative healthcare innovations with potential for significant returns.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Angelini Ventures is the corporate venture capital arm of Angelini Industries, deploying €300 million globally into BioTech and HealthTech companies. It invests primarily in Series A and Series B rounds, taking active involvement alongside entrepreneurs to scale healthcare innovations across Europe, North America, and Asia. The firm also operates venture studios (Extend, Argobio) and runs a Fellows Program for MD/PhD candidates.

Product overview

Angelini Ventures is a venture capital firm that operates as a single unified investment platform under Angelini Industries, deploying €300 million globally across BioTech and HealthTech companies. The firm offers venture capital investment services as its core product, supplemented by two venture studio programs (Extend and Argobio) that identify and incubate early-stage biotechnology projects, and a Fellows Program providing venture capital internship opportunities for MD and PhD candidates. The investment platform focuses on Series A and Series B rounds in companies operating in digital health, life sciences, tech-enabled care delivery, and connected devices, with particular emphasis on CNS disorders, mental health, and segments targeting women, children, and the elderly.

Differentiator

Problem solved

Functional benefit

Products and services

• Angelini Ventures Investment Services
• Extend Venture Studio
• Argobio Venture Studio
• Angelini Lumira Bioscience Fund
• Fellows Program

Quantifiable outcome

• 51% reduction in falls immediately after installation in care facilities using Nobi smart lamps
• +2 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Seven partnerships are on record, tiered core and minor.

• EvoteccoreStrategic or Co-development Partner · 28 October 2022Joint venture 'Extend' - translational BRIDGE partnership to develop drug discovery partnerships with Italian universities and research centers. Uses Evotec's technology platforms to accelerate translation of academic innovation.
• Enterprise SingaporeminorStrategic or Co-development PartnerGovernment agency supporting Singapore biotech ecosystem development through partnership with Angelini Ventures Singapore office for early-stage venture investments.
• AI SingaporeminorStrategic or Co-development PartnerNational AI program partnering with Angelini Ventures Singapore office, leveraging AI-powered platform for investment decisions.
• CEMMminorStrategic or Co-development PartnerInterdisciplinary research institute of Austrian Academy of Sciences committed to advancing understanding of human diseases through basic and biomedical research.
• Imec IstartminorChannel Partner/ Reseller/ DistributorOpen accelerator program offering tech startups pre-seed funding and tailored support to succeed and grow globally.
• Vita Digital Health AcceleratorminorChannel Partner/ Reseller/ DistributorDigital Health Accelerator of CDP National Accelerators Network, born from initiative of CDP Venture Capital together with Healthware Group and Accelerace.
• Digital MagicsminorChannel Partner/ Reseller/ DistributorLeading Italian incubator and accelerator supporting launch and scale of digital and technology focused ventures.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim investing in early-stage biotech, digital health, and preventive healthcare. Directly comparable to Angelini Ventures in corporate-backed healthcare VC focus, Elia Stupka previously worked at Boehringer Ingelheim Pharma.
• Debiopharm Innovation Fund: Swiss-based corporate venture capital arm of Debiopharm focused on digital health and biotech early-stage investments. Highly comparable as both firms invest in Series A/B healthcare companies globally with active involvement; Tanja Dowe and Hamzeh Abdul Hadi both previously worked at Debiopharm Innovation Fund before joining Angelini Ventures.
• Roche Venture Fund: Corporate venture arm of Roche investing in innovative therapeutic and diagnostic companies at early stages. Directly comparable as a global pharma corporate VC with Series A/B focus in biotech and healthtech, similar investment thesis and stage.
• CDP Venture Capital: Italian venture capital asset management company with over €1.8B in AUM. Directly comparable as a co-investor and JV partner (Extend partnership) and as an Italian-headquartered active healthcare investor sharing the same geographic base and biotech ecosystem as Angelini Ventures.
• Novartis Venture Fund: Corporate venture capital arm of Novartis investing in early-stage biotech and digital health. Directly comparable to Angelini Ventures as a pharmaceutical corporate VC deploying capital into Series A/B therapeutic and digital health startups globally.
• Hikma Ventures: Corporate venture capital arm of Hikma Pharmaceuticals investing in digital health and therapeutics. Directly comparable as a Middle East-based pharma CVC; Hamzeh Abdul Hadi spent nearly six years at Hikma Ventures before joining Angelini Ventures as Senior Principal in Dubai.
• Sanofi Ventures: Corporate venture capital arm of Sanofi investing in biotech and digital health startups. Comparable as a global pharma corporate VC with early-stage Series A/B focus across therapeutic areas overlapping with Angelini Ventures' portfolio.
• Merck KGaA M Ventures: Corporate venture arm of Merck KGaA investing in early-stage biotech and technology platforms. Directly comparable as a global corporate VC with sector focus on life sciences and healthcare innovation at Series A/B stages.
• J&J Innovation (JJDC): Venture arm of Johnson & Johnson investing across biotech, medical devices, and digital health globally. Comparable as a leading pharma corporate VC with broad healthcare mandate and significant capital deployment capabilities similar in scale and stage to Angelini Ventures.

Emerging players

• Wellington Partners Life Sciences: European life sciences-focused venture capital firm where Managing Director Regina Hodits previously worked as Managing Partner. Comparable as a healthcare-specialized early-stage investor with portfolio overlap in CNS, oncology, and biotech; functions as both a peer and a relationship node for Angelini Ventures.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/angelini-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments34 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Angelini Ventures